The global Sertraline market size was valued at USD 2.45 billion in 2025and is expected to reach USD 3.28 billion by 2033, at a CAGR of 3.75% during the forecast period

The market growth is largely fueled by the increasing prevalence of depression, anxiety disorders, panic disorder, and obsessive-compulsive disorder (OCD), leading to rising demand for effective and well-tolerated antidepressant therapies such as Sertraline across global healthcare systems

Furthermore, growing awareness regarding mental health treatment, expanding access to psychiatric care services, and increasing preference for selective serotonin reuptake inhibitors (SSRIs) due to their proven efficacy and favorable safety profile are establishing Sertraline as a widely used first-line treatment option. These converging factors are accelerating the uptake of Sertraline solutions, thereby significantly boosting the industry's growth